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REPLY
We thank Dr. Alfonso for his comments about our study (1). His
observations provide an opportunity: 1) to analyze the implications
of the procedural finding of balloon slippage in patients with
in-stent restenosis (ISR) treated by conventional balloon angio-
plasty; 2) to report whether a specific subgroup of patients
benefited from cutting balloon angioplasty; and 3) to discuss the
possible benefit of lesion pre-dilation using the cutting balloon in
patients with ISR treated with drug-eluting stenting.
First, analysis of the Restenosis Cutting Balloon Evaluation
Trial (RESCUT) database shows that in the group treated with
conventional balloon angioplasty, balloon slippage was associated
with a higher percentage, although not statistically significant, of
residual dissections (11.1% vs. 6,9%; p  0.35), and a higher
percentage of additional stent implantation (9.5% vs. 3.5%; p 
0.21) mainly due to type D, E, and F dissections. However,
recurrent restenosis rate at six months was not higher when balloon
slippage was observed.
Second, the analysis performed with the multivariate technique
to determine whether any specific subset of ISR patients/lesions
benefited from the cutting balloon treatment (i.e., short vs. long
lesions, small vs. large vessel, diabetics vs. nondiabetics, short time
vs. long time by previous implanted stent, first vs.1 prior ISR on
the same vessel) did not uncover any significant effect.
Third, although a recent study failed to demonstrate long-term
benefits after the use of cutting balloon in ISR patients undergoing
adjunctive gamma brachytherapy (2), in the Registry Novoste
(RENO) (3) where brachytherapy was performed using beta-
radiation, pretreatment with cutting balloon significantly reduced
six-month target-vessel revascularization compared with conven-
tional angioplasty (10.2% vs. 16.6%; p  0.04).
However, we do not believe that the use of cutting balloon will
translate into clinical or angiographic benefit for patients with ISR
treated with drug-eluting stents (DES), as a result of the proce-
dural differences in the treatment of ISR using adjunctive brachy-
therapy compared with restenting with a DES. In the first case,
before adjunctive brachytherapy, it is recommended to optimally
treat ISR by conventional/cutting balloon angioplasty or atherec-
tomy, avoiding additional stenting to reduce the risk of late stent
thrombosis, whereas in the case of restenting with a DES, an
optimal balloon pretreatment of ISR is not necessary, nor is the use
of cutting balloon to avoid balloon slippage, because the operator
can reduce the risk of vessel injury at the stent edges, even in the
event of balloon slippage, by simply predilating the ISR lesion
using an undersized noncompliant conventional balloon.
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Rate Control in Atrial Fibrillation
We read with great interest the substudy of the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM)
investigators on the approaches to control rate in atrial fibrillation
(AF) (1). Recent studies show that rate control may be adopted as
first-choice therapy in a variety of patients with AF (2,3). The
optimal level of heart rate during AF is, however, still unknown.
In the AFFIRM study, in accordance with the guidelines (4), a
strict rate-control approach was applied that includes a resting
heart rate 80 beats/min and either a 6-min walk test heart rate
110 beats/min or a mean heart rate on a 24-h Holter recording
100 beats/min, in combination with a maximum heart rate
110% of predicted maximum heart rate. The present study shows
that this (strict) rate-control approach can be successfully achieved
in two-thirds of the patients and that, in line with previous data,
beta-blockers are most effective to accomplish this goal (5). Serious
adverse effects were uncommon. However, to obtain adequate rate
control, atrioventricular node ablation and pacemaker implantation
was performed in 108 of the 2,027 patients (5.3%), and an
additional 147 patients (7.3%) had a pacemaker implanted for
symptomatic bradycardia. In comparison, in the RAte Control
versus Electrical cardioversion (RACE) study, a more lenient
rate-control approach was followed (resting heart rate 100
beats/min) (3). In that study, 46% of the patients were treated with
a beta-blocker. Severe drug adverse effects were also rare (0.8%). In
contrast to the AFFIRM study, however, a pacemaker was
implanted in only 3 of the 256 patients (1.2%, all after atrioven-
tricular node ablation).
Unfortunately, the AFFIRM investigators give no data on the
influence of the level of rate control on mortality and morbidity.
Therefore, it still, remains unknown whether strict rate control is
associated with an improved prognosis. To answer the question of
which approach to rate control is most effective we will start the RAte
Control Efficacy in permanent atrial fibrillation study (RACE II).
*Isabelle C. Van Gelder, MD
Michiel Rienstra, MD
Maarten P. Van den Berg, MD
Dirk J. Van Veldhuisen, MD, FACC
*Department of Cardiology
Thoraxcenter
University Hospital Groningen
P.O. Box 30.001
9700 RB Groningen
The Netherlands
E-mail: i.c.van.gelder@thorax.azg.nl
doi:10.1016/j.jacc.2004.09.024
2417JACC Vol. 44, No. 12, 2004 Correspondence
December 21, 2004:2410–9
